Novartis India targets therapy-aligned acquisitions and expansion into Tier 2 and Tier 3 markets

Novartis India is looking at therapy-aligned acquisition opportunities while seeking to deepen its presence in India's Tier 2 and Tier 3 markets.

The company's growth strategy combines potential acquisitions that complement its therapeutic focus with greater penetration beyond India's largest metropolitan markets.

The plans signal a broader effort by Novartis India to strengthen its domestic footprint while maintaining alignment with priority therapy areas.

Field	Content
Alert Type	Corporate strategy update
Company	Novartis India
Industry Area	Pharmaceuticals
Geography	India
Strategic Focus	Therapy-aligned acquisitions and expansion into Tier 2 and Tier 3 markets
What Happened	Novartis India outlined plans to explore acquisition opportunities aligned with its therapeutic priorities while expanding its presence in Tier 2 and Tier 3 markets.
Why It Matters	The strategy could broaden Novartis India's domestic reach and provide additional growth opportunities while keeping potential acquisitions aligned with the company's existing therapeutic focus.
Supporting Context	The acquisition plans are prospective rather than a completed transaction, making the development a corporate strategy update rather than a Deals announcement.
Key Takeaway	Novartis India is pursuing a two-pronged growth strategy centred on therapy-aligned acquisition opportunities and deeper penetration of markets outside India's largest cities.
What to Watch	Potential acquisition targets and the execution of Novartis India's expansion strategy across Tier 2 and Tier 3 markets.
Primary Source	Business Standard
Relevant Date	6 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com